BRCA1 and ovarian cancer: ART558 is a small-molecule Polθ inhibitor that has a synergistic effect with PARPi, and it has a stronger inhibitory effect on cells (including ovarian cancer and breast cancer cells) when used at the same time in BRCA1/2 mutant cells.